SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 10-Q/A
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1997
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____
Commission file number 0-21379
CUBIST PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware 22-3192085
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
24 Emily Street
Cambridge, Massachusetts 02139
Address of principal executive offices (Zip Code)
Registrant's telephone number, (617) 576-1999
including area code:
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months, and (2) has been subject to such filing
requirements for the past 90 days.
YES X NO ____
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
Common Stock, $.001 par value 9,556,395
Class Outstanding at May 1, 1997
<PAGE>
In response to the comments of the Commission's staff (the "Staff") by
letter dated November 24, 1997, and a telephone conversation with Darren de
Stefano, Staff Attorney with the Commission, the Company hereby withdraws, by
amendment, Exhibits 10.1 and 10.2 from its Quarterly Report on Form 10-Q for
the period ended March 31,1997. The Agreements set forth in the
above-referenced Exhibits have terminated, and are, therefore, no longer
material to the Company's business.
PART II--OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
11--Statement of Computation of Earnings Per Share
27--Financial Data Schedule
(b) Reports on Form 8-K
No more reports on Form 8-K were filed by the Company during the quarter
ended March 31, 1997.
Exhibit 10.1 withdrawn
Exhibit 10.2 withdrawn
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant had duly caused this report to be signed on its behalf by the
undersigned, thereto duly authorized.
CUBIST PHARMACEUTICALS, INC.
Date:December 12, 1997 By:/s/ Thomas A. Shea
Thomas A. Shea
Director of Finance &
Administration
(Authorized Officer and Principal
Finance and Accounting Officer)
